Diamyd, with R&D here, inks $625M deal with J&J
Diamyd Medical AB, a Stockholm, Sweden-based company that maintains its research and development facilities in Pittsburgh, secured a major deal with a unit of Johnson & Johnson to develop and commercialize Diamyd's diabetes therapy.
The agreement over time could be worth more than $625 million to Ortho-McNeil-Janssen Pharmaceuticals Inc., the company said.
Diamyd came to Pittsburgh in 2005 when it acquired Nurel Therapeutics, founded by University of Pittsburgh scientists.
Darren Wolfe, CEO of Diamyd Inc. USA, said his R&D unit has more than doubled its work force in the last six months, to seven, and expects to employ 10 to 12 people within a year.
The company is housed within the Pittsburgh Life Sciences Greenhouse incubator at the Pittsburgh Technology Center in South Oakland. The Greenhouse also is an investor in Diamyd, having placed $100,000 in the local operations.
Show commenting policy
TribLive commenting policy
- Ford City budget may not be final
- 2,200 union employees of ATI lose coverage
- Angel trees feature pets from shelter
- Babies welcomed to the world in holiday style
- November spared Valley effects of wintry weather
- Mentor takes young Brackenridge hunter under his wing
- Eastern Pa. man jailed in Armstrong County
- Shoppers can buy gifts for seniors through Home Instead program
- Starkey: Tomlin lived in his fears
- Demand for surveillance systems boosts sales for Vector Security
- Penguins’ reshuffled top line of Crosby, Dupuis, Kunitz looks familiar